In recent years, China’s innovative pharmaceutical industry has undergone rapid transformation, shifting from a reliance on generic drugs to a high-quality development model driven by independent R&D. Bolstered by supportive government policies, increased capital investment, the return of overseas talent, and vast clinical resources, Chinese pharmaceutical companies have achieved breakthroughs in multiple therapeutic areas—including oncology, autoimmune diseases, rare disorders, and anti-infectives. Companies such as BeiGene, Innovent Biologics, and Hengrui Medicine now hold significant positions not only in the domestic market but also globally, with their self-developed drugs receiving approvals from major international regulatory bodies like the U.S. FDA and the European Medicines Agency (EMA). For instance, BeiGene’s BTK inhibitor zanubrutinib became the first fully China-developed anticancer drug to gain FDA approval, marking a milestone in China’s global pharmaceutical presence. Furthermore, Chinese firms are deepening their integration into the global innovation ecosystem through partnerships with multinational pharma companies, overseas manufacturing facilities, and participation in international multicenter clinical trials. Today, China is no longer a mere follower in the global pharmaceutical supply chain but an increasingly central force driving worldwide drug innovation.
近年来，中国创新药产业迅猛发展，已从过去的仿制药为主转向以自主研发为核心驱动力的高质量发展阶段。凭借政策支持、资本投入、人才回流以及庞大的临床资源，中国药企在肿瘤、自身免疫、罕见病和抗感染等多个治疗领域取得突破性进展。百济神州、信达生物、恒瑞医药等企业不仅在国内市场占据重要地位，其自主研发的新药也陆续获得美国FDA、欧洲EMA等国际权威监管机构的批准，成功进入全球主流市场。例如，百济神州的BTK抑制剂泽布替尼成为首个完全由中国本土研发并获FDA批准上市的抗癌新药，标志着中国创新药真正走向世界。此外，中国药企还通过与跨国制药公司合作、海外建厂、参与国际多中心临床试验等方式，深度融入全球医药创新体系。如今，中国已不再是全球医药产业链的‘追随者’，而是日益成为推动全球新药研发的重要力量，在全球创新药版图中占据核心位置。
原创文章，作者：admin，如若转载，请注明出处：https://avine.cn/16703.html